Issue 7, 2011

FDA-approved poly(ethylene glycol)–protein conjugate drugs

Abstract

PEGylation or covalent attachment of poly(ethylene glycol) improves the pharmacokinetic properties of protein drugs. In vivo circulation lifetimes are increased and dosages are decreased, resulting in improved patient quality of life. PEG may be attached to proteins using a variety of different chemical reactions. This review discusses currently available FDA-approved PEGylated protein drugs, their intended use and target, and the PEG attachment chemistry utilized.

Graphical abstract: FDA-approved poly(ethylene glycol)–protein conjugate drugs

Article information

Article type
Review Article
Submitted
21 Jan 2011
Accepted
20 Mar 2011
First published
27 Apr 2011

Polym. Chem., 2011,2, 1442-1448

FDA-approved poly(ethylene glycol)–protein conjugate drugs

S. N. S. Alconcel, A. S. Baas and H. D. Maynard, Polym. Chem., 2011, 2, 1442 DOI: 10.1039/C1PY00034A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements